Mortalin: Protein partners, biological impacts, pathological roles, and therapeutic opportunities

Front Cell Dev Biol. 2023 Feb 2:11:1028519. doi: 10.3389/fcell.2023.1028519. eCollection 2023.

Abstract

Mortalin (GRP75, HSPA9A), a heat shock protein (HSP), regulates a wide range of cellular processes, including cell survival, growth, and metabolism. The regulatory functions of mortalin are mediated through a diverse set of protein partners associated with different cellular compartments, which allows mortalin to perform critical functions under physiological conditions, including mitochondrial protein quality control. However, alteration of mortalin's activities, its abnormal subcellular compartmentalization, and its protein partners turn mortalin into a disease-driving protein in different pathological conditions, including cancers. Here, mortalin's contributions to tumorigenic pathways are explained. Pathology information based on mortalin's RNA expression extracted from The Cancer Genome Atlas (TCGA) transcriptomic database indicates that mortalin has an independent prognostic value in common tumors, including lung, breast, and colorectal cancer (CRC). Subsequently, the binding partners of mortalin reported in different cellular models, from yeast to mammalian cells, and its regulation by post-translational modifications are discussed. Finally, we focus on colorectal cancer and discuss how mortalin and its tumorigenic downstream protein targets are regulated by a ubiquitin-like protein through the 26S proteasomal degradation machinery. A broader understanding of the function of mortalin and its positive and negative regulation in the formation and progression of human diseases, particularly cancer, is essential for developing new strategies to treat a diverse set of human diseases critically associated with dysregulated mortalin.

Keywords: cancer; cellular localization; mortalin (HSPA9); post-translational modification (PTM); protein partners.

Publication types

  • Review

Grants and funding

The support for this work was provided by the University of South Dakota Division of Basic Biomedical Sciences (READ award) and CBBRe (Center for Brain and Behavior Research, University of South Dakota). The DaCCoTA funding is supported by the National Institute of General Medical Sciences of the National Institutes of Health under award number U54GM128729 and the National Cancer Institute of the National Institutes of Health under award number 1R03CA223935-01. Additionally, this research was supported, in part, by a grant from the National Science Foundation (DGE-1633213).